Test Price
2,800 AED✅ Home Collection Available
GLRX5 Gene NGS Test for Pyridoxine‑Refractory Sideroblastic Anemia – Dubai, UAE
Executive Summary & Core Metrics
DNA Labs UAE delivers definitive molecular diagnosis for autosomal recessive pyridoxine‑refractory sideroblastic anemia through comprehensive GLRX5 gene sequencing. Our ISO‑accredited, DHA‑licensed laboratory guarantees 99.9% diagnostic sensitivity and full regulatory compliance with UAE healthcare data protection laws.
- Accuracy Guarantee: 99.9% analytical sensitivity and specificity via ISO‑certified processing pipeline.
- Premium Logistics: VIP Mobile Phlebotomy and temperature‑controlled cold‑chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Post‑test telephonic consultation with a board‑certified medical geneticist for result interpretation.
- Insurance Verification: Direct billing confirmation via WhatsApp +971 54 548 8731.
- DHA Licensed Facility: Premises 105, Floor 1, Building 33, Dubai Healthcare City – License No. 1143.
Test Overview & Methodology
The GLRX5 NGS test sequences the entire coding region and all exon‑intron boundaries of the GLRX5 gene to detect pathogenic variants causative of autosomal recessive pyridoxine‑refractory sideroblastic anemia. Results provide definitive molecular confirmation, enabling precise iron management, family risk stratification, and informed reproductive decision‑making for patients across the UAE.
| Feature | This Test (GLRX5 NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Diagnostic Precision | 99.9% analytical sensitivity and specificity across entire gene | ~99% for targeted region; may miss large deletions or deep intronic variants |
| Methodology | Next‑Generation Sequencing (NGS) – comprehensive coverage of coding regions and splice sites | Sanger sequencing – limited to one amplicon per reaction; low throughput |
| Turnaround Time | 3 – 4 Weeks | 4 – 6 Weeks (if reflex or supplementary testing is required) |
Physician Insight & Safety Protocols
“Identifying the molecular cause of pyridoxine‑refractory sideroblastic anemia transforms uncertainty into actionable clinical clarity. This NGS‑based test empowers hematologists to tailor iron‑chelation therapy, avoid ineffective supplements, and provide precise recurrence risk counseling for families. Every result is interpreted alongside the full hematological presentation to ensure safe, individualized care.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)
Advisory: Medication Continuation & Clinical Context
Do not discontinue any prescribed therapy (including pyridoxine, iron chelators, or erythropoiesis‑stimulating agents) without consulting your treating physician. Genetic test results provide supplementary diagnostic information and must never replace independent clinical judgment or emergency medical evaluation.
Exclusion Criteria & Emergency Red Flags
- Recent hematopoietic stem cell transplant (within 100 days) – donor‑derived DNA may confound germline interpretation.
- Active chemotherapy causing severe leukopenia – sample quantity or quality may be insufficient.
- Repeat testing required if blood transfusion occurred within 2 weeks before collection (pre‑transfusion sample is strongly preferred).
- Seek immediate emergency care for severe shortness of breath, chest pain, confusion, or loss of consciousness – these signs may indicate life‑threatening anemia requiring acute intervention.
Patient FAQ & Clinical Guidance
1. What is the GLRX5 gene NGS test and how accurate is it?
This test uses next‑generation sequencing to examine the complete coding region and splice junctions of the GLRX5 gene, detecting point mutations, small insertions or deletions, and copy number variants responsible for hereditary pyridoxine‑refractory sideroblastic anemia. It achieves 99.9% analytical sensitivity and specificity, providing a definitive molecular diagnosis that guides targeted iron management and enables cascade screening of at‑risk relatives.
2. How should I prepare for the test and is home collection available in the UAE?
No fasting is required. A peripheral whole blood sample or buccal swab can be collected at your residence by our DHA‑licensed phlebotomists between 8 AM and 11 PM, utilizing validated temperature‑controlled cold‑chain transport. Please inform us of any recent blood transfusions or stem cell transplant. A pre‑test genetic counseling session (telehealth or in‑person) will be scheduled to document your family pedigree and explain the autosomal recessive inheritance pattern.
3. Will my insurance cover this test and how long until I receive results?
We perform direct insurance verification via WhatsApp; many UAE health insurers reimburse medically necessary genetic testing when a physician referral is provided. The typical turnaround time is 3 to 4 weeks from sample receipt at our Dubai Healthcare City laboratory. Once completed, a board‑certified molecular geneticist interprets the report and discusses the findings with your referring physician during a tele‑consultation to explain clinical implications for you and your family members.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly complies with all applicable UAE federal data protection and healthcare technology regulations governing genetic testing, patient data processing, and clinical consent:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governs the lawful collection, storage, and processing of patient genomic and clinical data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – mandates secure handling of electronic health records and telehealth communications.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – establishes the legal framework for clinical testing safety, informed consent, and patient rights.
All genetic data are encrypted, access‑restricted, and retained only for the lawful purpose of clinical diagnosis and follow‑up care. No data is shared with third parties without explicit patient consent.
Clinical & Logistical Metadata
| Test Name | GLRX5 Gene NGS Test (Pyridoxine‑Refractory Sideroblastic Anemia) |
| Price (AED) | 2,800 |
| Turnaround Time | 3 – 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood or Buccal Swab |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full Coding Region & Splice Sites |
| ICD‑10‑CM Code | D64.0 |
| LOINC Code | 55233-1 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians